NICE says it can approve BioMarin's ultra-rare drug treatment Vimizim, but has proposed real-world data collection and a price cap to overcome doubts about the drug's value, reports Andrew McCo
NICE is to establish a new Office for Market Access to help life sciences companies prepare for its cost effectiveness appraisals and improve their chances of gaining a 'yes'.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
